Medindia

X

Oncolytics Biotech® Inc. Reports Preliminary Data from Randomized Phase II Study of REOLYSIN® in Non-Small Cell Lung Cancer

Thursday, May 19, 2016 Respiratory Disease News J E 4
Advertisement

Source: Report of Statistical Analysis for NCIC CTG Protocol Number IND.211

1 This was an interim analysis, as 38 (25.0%) patients out of a total of 152 patients were alive at the time of data cut-off. Survival outcomes noted could change at final analysis.

2 Mutated

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Lyme Bacteria Hides Inside Parasitic Worms, Causin...
S
Dr. Pankaj Naram Asks if There Is a Smart Way to L...